Events

Virtual Cybersecurity B2B Meetings & Webinar
MAY
Mon
19
MAY
Tue
20
MAY
Wed
21

This was 6 months ago

Location

Online

Programmes
Security Cybersecurity

The Enterprise Europe Network and SeREN5, the HorizonEurope NCPs Network for Cluster 3 research Civil Security for Society organise a twofold Virtual Cybersecurity B2B event

The event consists of

  • a fully virtual B2B event where participants can profile their offers and requests of collaboration, first ideas to set-up consortia and good proposals, with the help of both Enterprise Europe Network and Horizon Europe Cluster 3 NCPs
  • a hands-on, awareness-raising webinar on the forthcoming calls on topics related to the cybersecurity (Destination - Increased Cybersecurity) by SeREN5 network representative (19 May 2025, 10.00-12.00).

Participation is free of charge, but mandatory via this link.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.